Cancer Drugs Boost Bayer Despite Crop, Consumer and Currency Concerns
The still pending acquisition of Monsanto, crop science problems in Brazil and a weak showing from consumer health in the US cannot disguise the strong growth that Bayer's pharmaceuticals business is continuing to enjoy.
You may also be interested in...
PD-1 inhibitor performance and the intense curiosity around AstraZeneca both for its MYSTIC trial and Soriot's faithfulness to the company are key themes at the half-year mark. Eyes are also on commercial performance for Roche's Ocrevus and Merck's anacetrapib for clarity on whether it has a commercial future.
J&J will be talking to FDA regarding expanded approval for peripheral arterial disease and coronary artery disease following early stop of COMPASS outcomes study; strong data will be needed if asymptomatic patients are targeted.
Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."